Use of Cardiac Resynchronisation Therapy - Change of Clinical Settings

Area of Science:

• Cardiology
• Electrophysiology
• Heart Failure Management

Background:

• Current guidelines recommend cardiac resynchronisation therapy (CRT) for severe heart failure (HF) with specific ECG criteria (QRS duration ≥120-150 ms) and NYHA class III-IV symptoms.
• Existing evidence suggests potential benefits of CRT in expanding patient populations.

Purpose of the Study:

• To review the current evidence for expanding the use of CRT.
• To evaluate CRT's role in patients with asymptomatic left ventricular dysfunction, atrial fibrillation, narrow QRS duration, right bundle branch block (RBBB), and end-stage renal disease on dialysis.

Main Methods:

• Systematic review of existing studies and clinical trials.
• Analysis of data concerning CRT efficacy in diverse HF patient subgroups.

Main Results:

• Studies indicate potential benefits of CRT in patients with asymptomatic left ventricular dysfunction.
• Evidence is emerging regarding CRT's implications in patients with atrial fibrillation, narrow QRS, RBBB, and end-stage renal disease.

Conclusions:

• The evidence supports further investigation into expanding CRT indications.
• Tailoring CRT strategies for specific patient profiles, including those outside current guidelines, is crucial for optimizing HF management.